Shortly after we made a diagnosis of bullous pemphigoid in this minipig, we found that a second minipig in the colony had similar, but less severe, lesions. Again, we did not administer ...

COVID-19 survivors may develop autoimmune conditions long-term, with risks varying by severity and vaccination status, ...

COVID-19 is associated with long-term risk for autoimmune and autoinflammatory connective tissue disorders, according to a ...

Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as a tool to ...

OCT for early diagnosis and characterization of dermatologic adverse events to oncologic drugs and correlation to ...

Bullous keratopathy is a sight-threatening and debilitating condition affecting the endothelial cells of the cornea. Bullous keratopathy causes the accumulation of water in the form of blisters on ...

Vascular space involvement, venous or lymphatic, does not affect classification. ‡ The presence of bullous edema is not sufficient to classify a tumor as T4. Table 2. Studies Investigating the ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...